



ASX Release

Highlights

CLINICAL TRIAL OF **ArTiMist™** ANTI MALARIA TREATMENT UPDATE

Eastland Medical Systems Ltd (ASX:EMS) announces today that it has received advice from Mr. Calvin Ross R&D Director of ProtoPharma Ltd our project consultant, and newly appointed Non-Executive Director of Eastland, following his third visit to Rwanda to review progress of the trial, that he notes that the enrolment rate of children for the trial has been faster than expected,

Based on this recent review it is now expected that we will be able to inform the market on the progress and initial findings of the trial in early February 2010.

Further information:

Dermot Patterson
CEO and Company Secretary
Eastland Medical Systems Ltd
t: +61 8 9436 9500
www.eastlandmedical.com.au

- Phase 1 multi-dose clinical trials for **ArTiMist™** were undertaken in South Africa in February 2008 with positive results indicating the formulation was well tolerated and showed no adverse effects in any of the trial subjects.
- Clinical Field Trial has commenced in Rwanda.

For personal use only